Every 10-Q that Outlook Therapeutics, Inc. (OTLK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OTLK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OTLK filings page.
Outlook Therapeutics, Inc. (OTLK) reported continued operating losses while advancing LYTENAVA, its ophthalmic bevacizumab, toward broader commercialization. For the nine months ended June 30, 2026, net loss was $47.8 million versus $49.1 million a year earlier, with revenues, net of gross‑to‑net adjustments, of $(1.1) million compared with $1.5 million, driven largely by reserve changes and low early European sales. Operating cash outflow was $43.8 million, and cash and cash equivalents were $11.2 million at June 30, 2026.
Total assets were $26.2 million against $36.6 million of liabilities, leaving a stockholders’ deficit of $10.4 million. Management disclosed substantial doubt about the ability to continue as a going concern, citing recurring losses, a working capital deficit, and outstanding obligations including an unsecured promissory note to Atlas Sciences with $20.3 million of principal, accrued interest and exit fees outstanding and maturing in June 2027. The company has been funding operations primarily through equity, warrant exercises, and debt, including multiple 2026 offerings and a new at‑the‑market program.
Strategically, Outlook expanded its intellectual property portfolio and continued commercial rollout of LYTENAVA in Europe. Critically, in July 2026, after quarter‑end, the FDA approved LYTENAVA (bevacizumab‑vikg) as the first FDA‑approved ophthalmic bevacizumab for wet AMD in the United States, conferring 12 years of U.S. regulatory exclusivity. The company is preparing a U.S. launch before December 31, 2026 and subsequently raised approximately $51.1 million in an August 2026 follow‑on equity and warrant offering to help fund commercialization and general corporate purposes.
Outlook Therapeutics reported a net loss of $23.1 million for the quarter ended December 31, 2025, compared with net income of $17.4 million a year earlier, driven largely by fair value losses on its convertible note and warrant liability.
Net revenue was negative $1.2 million after a $1.1 million returns reserve increase on UK product and distributor fees, while research and development and selling, general and administrative expenses fell to $3.6 million and $8.6 million, respectively. Cash and cash equivalents were $8.7 million against total liabilities of $56.8 million, leaving a stockholders’ deficit of $38.5 million and prompting substantial doubt about continuing as a going concern.
The company is commercializing LYTENAVA in Germany and the UK but has received three FDA Complete Response Letters for ONS-5010/LYTENAVA in wet AMD and has requested another Type A meeting to discuss potential regulatory pathways. It also triggered a “Major Trigger Event” under its March 2025 unsecured convertible promissory note, increasing the outstanding balance and resetting the conversion pricing formula.
Outlook Therapeutics, Inc. (OTLK) reports commercial availability of LYTENAVA (bevacizumab gamma) in Europe in fiscal 2025 and recognizes revenue when product is delivered to pharmaceutical wholesalers, with returns, rebates and administrative fees contractually applied. The company has 260,000,000 shares authorized and reported 43,479,051 shares issued and outstanding at June 30, 2025 versus 23,905,635 at September 30, 2024.
The filing details multiple financing transactions in 2025 including a public offering that generated net proceeds of $11,625,229, ATM capacity with $88,301,796 remaining as of June 30, 2025, and several warrant inducement transactions that produced net proceeds and resulted in mark-to-market and inducement charges (including $27,711,889 and $4,196,868 recorded for the nine months ended June 30, 2025). The company notes a March 2025 Note with conversion mechanics, high default interest (22% per annum) and potential dilution triggers. A securities class action is pending and a motion to dismiss is under review.